PARK7 and breast cancer: In this sense, it should be recommendable to include in the same diagnostic/prognostic panel, promiscuous cancer specific autoantibodies as p53, MUC1, NY-ESO-1, MAGEA1, and Survivin, among others, together with specific autoantibodies of different cancer types as HER2 or BRCA2 in BC, SOX2, or GBU4-5 in LC, AMACR, or PARK7 in PC, and CEA, PIM1, or GTF2B in CRC to be able to detect not only cancer but its exact localization.